Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | JUN | P05412 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1985611 | 0.81 | PADI4 (0.31) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1986086 | 0.80 | CYP1A2 (0.30) | — | |
| SCHEMBL1985449 | 0.74 | SIGMAR1 (0.53) | JUNMAPK10 | |
| SCHEMBL1986344 | 0.69 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1986919 | 0.65 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA3CHRNA7 | |
| SCHEMBL1990026 | 0.65 | JUN (0.37) | JUNMAPK10PARP14PDK2BRD4 | |
| SCHEMBL1985022 | 0.64 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA3CHRNA7 | |
| SCHEMBL1991565 | 0.62 | MCHR1 (0.40) | — | |
| SCHEMBL1987185 | 0.61 | SIGMAR1 (0.49) | CHRNB2CHRNA3BRD4 | |
| SCHEMBL9429745 | 0.61 | ENPP3 (0.50) | JUNMAPK10PDK2NPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152306-A1 | AZA-BRIDGED RING-FUSED INDOLES AND INDOLINES | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | claimed |
| US-8778959-B2 | AZA-bridged ring-fused indoles and indolines | ABBVIE INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20110152306-A1 | AZA-BRIDGED RING-FUSED INDOLES AND INDOLINES | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152306-A1 | AZA-BRIDGED RING-FUSED INDOLES AND INDOLINES | INMT, IDO1, IDO2 | CHRNB2 549/4885CHRNA4 353/4885CHRNB4 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.